Anxiety disorders and depression are the most common mental health conditions in the United States — affecting tens of millions of adults every year. Yet despite decades of research, clinical advances, and growing public awareness, a significant gap between the people who could benefit from treatment and those who actually receive it persists.
Part of the challenge is the sheer volume of information — and misinformation — about what works. From social media wellness culture to pharmaceutical advertising to well-meaning but oversimplified advice, it can be difficult to know what the actual science says about treating anxiety and depression effectively.
This blog is an attempt to provide that clarity — drawing on peer-reviewed evidence, clinical guidelines, and the perspective of a mental health care team committed to genuinely helping people get better.
First: Understanding These Conditions
Anxiety Disorders
Anxiety disorders are not a single condition — they’re a category of related conditions that includes generalized anxiety disorder (GAD), social anxiety disorder, panic disorder, specific phobias, and others. What these conditions share is excessive, persistent fear or worry that is disproportionate to actual circumstances and that meaningfully interferes with daily functioning.
An important clinical distinction: the experience of anxiety — normal nervousness, worry, or stress — is a universal human experience. Anxiety becomes a disorder when the anxiety response is persistent, excessive relative to the actual threat, difficult to control, and causes significant distress or impairment in work, relationships, or daily activities.
Anxiety disorders affect approximately 19 percent of U.S. adults annually, according to NIMH statistics, and they are among the most common mental health conditions in the country. Yet a significant share of those affected do not receive treatment.
Major Depressive Disorder
Depression is more than feeling sad. Major depressive disorder (MDD) is a clinical diagnosis characterized by persistently depressed mood or loss of interest in activities, present for at least two weeks, accompanied by several additional symptoms including changes in sleep, appetite, energy, concentration, self-worth, and — in severe cases — thoughts of death or suicide. MDD affects approximately 21.4 million American adults annually, according to SAMHSA’s 2024 NSDUH. It is among the leading causes of disability worldwide, and it significantly increases the risk of cardiovascular disease, diabetes, and early death when left untreated. Despite this, many people live with unmanaged depression for years before seeking or receiving appropriate care.
Evidence-Based Therapy: What Research Says Works
Cognitive Behavioral Therapy (CBT)
CBT is the most extensively studied psychotherapy for both anxiety and depression, and it consistently demonstrates effectiveness across multiple randomized controlled trials and meta-analyses. Developed by Dr. Aaron Beck in the 1960s, CBT is based on the principle that thoughts, feelings, and behaviors are interconnected — and that changing dysfunctional thought patterns and behavioral responses can alleviate psychological distress.
For anxiety, CBT typically incorporates psychoeducation, cognitive restructuring (identifying and challenging distorted thinking patterns), and exposure exercises — gradual, supported confrontation with feared situations or thoughts. Major meta-analyses have consistently found CBT significantly more effective than control conditions for anxiety disorders, with effect sizes considered large to very large across multiple presentations.
For depression, CBT addresses the negative cognitive triad — negative beliefs about the self, the world, and the future — that characterizes depressive thinking, alongside behavioral activation (increasing engagement with rewarding activities to counteract depressive withdrawal). Cochrane reviews of dozens of randomized controlled trials have found CBT significantly superior to control conditions for depression, with effects maintained at follow-up.
Acceptance and Commitment Therapy (ACT)
ACT, developed by Dr. Steven Hayes, is a newer approach that has accumulated a strong evidence base for both anxiety and depression. Rather than directly challenging the content of difficult thoughts, ACT focuses on developing psychological flexibility — the ability to accept difficult internal experiences without being controlled by them, and to commit to value-driven action even in the presence of discomfort.
Research supports ACT as an effective alternative to CBT for anxiety and depression, and it is particularly well-suited for individuals who have found direct cognitive challenging to feel invalidating or who are drawn to mindfulness-based approaches. Multiple randomized controlled trials have found ACT comparable to or superior to established treatments for a range of anxiety and depressive presentations.
Interpersonal Therapy (IPT)
IPT focuses on improving the quality of personal relationships and social functioning as a pathway to reducing depressive symptoms. Based on the empirically supported association between relationship quality and mood, IPT addresses grief, role transitions, interpersonal disputes, and social skill deficits. It has been shown in randomized controlled trials to be as effective as CBT for depression, and is particularly beneficial for individuals whose symptoms are closely tied to relational stressors.
Medication: Evidence, Appropriate Use, and Honest Limitations
Antidepressants for Depression
The most widely prescribed medications for depression are selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). These medications work by modulating neurotransmitter systems involved in mood regulation, and they have a substantial evidence base for moderate to severe depression.
A 2018 landmark meta-analysis published in The Lancet (Cipriani et al.) analyzed 522 trials involving over 116,000 participants and found that all 21 antidepressants studied were more effective than placebo for acute depression — with effect sizes ranging from moderate to large, particularly in severe presentations. The authors also found significant differences in tolerability and response between medications, reinforcing the importance of individualized prescribing.
An important nuance: antidepressants are most clearly effective for moderate to severe depression, and the evidence for mild depression is more mixed. For mild to moderate presentations, therapy alone may be as or more effective than medication alone, with better durability of outcomes. The most effective approach for many patients is a combination of therapy and medication — an evidence-based finding that should guide treatment planning rather than defaulting to medication alone.
Medications for Anxiety
SSRIs and SNRIs are also first-line pharmacological treatments for most anxiety disorders — a fact that surprises some patients who expect a different class of medication. Benzodiazepines (such as lorazepam, clonazepam, and diazepam) are sometimes used for acute anxiety relief but are not recommended for long-term management due to tolerance, dependence risk, and cognitive side effects. Current clinical guidelines consistently recommend SSRIs/SNRIs as first-line pharmacotherapy for anxiety disorders, with therapy as a concurrent or standalone option.
Buspirone is an effective non-benzodiazepine option for generalized anxiety disorder, with a more favorable side effect profile for long-term use. Beta-blockers like propranolol can be useful for situational anxiety (like performance anxiety) but are not effective for most anxiety disorders as primary treatments.
Emerging Treatments for Treatment-Resistant Cases
For the significant minority of patients whose depression or anxiety doesn’t respond adequately to standard treatments, the options have expanded substantially. In January 2025, the FDA approved esketamine (Spravato) as a standalone monotherapy for treatment-resistant depression — a meaningful expansion of its previous indication. Ketamine-assisted therapy, transcranial magnetic stimulation (TMS), and emerging research into psychedelic-assisted approaches are creating new pathways for patients who have not found relief through standard care.
At Vantage Telehealth, our mental health providers are equipped to evaluate and discuss these options with patients whose experiences with standard treatments have been disappointing. You don’t have to keep trying the same things and getting the same results.
The Role of Lifestyle in Mental Health Treatment
One of the most consistently supported findings in mental health research is that lifestyle factors — exercise, sleep, nutrition, social connection, and stress management — have significant and measurable effects on anxiety and depression, both as standalone interventions and as complements to therapy and medication.
Exercise, in particular, has a remarkably strong evidence base for mental health. Meta-analyses have found exercise comparable to antidepressants for mild to moderate depression in terms of symptom reduction. The American Psychological Association has long recommended exercise as a frontline intervention for mild to moderate depression.
Sleep and diet — explored in detail in our Lifestyle Coaching blog series — also have robust connections to mental health outcomes. This interconnection is one reason why integrated care that addresses lifestyle alongside medical treatment consistently produces better outcomes than medication or therapy alone.
Getting Care That Actually Fits Your Life
The best evidence in the world means little if care is inaccessible. At Vantage Telehealth, we’ve designed our mental health services around the practical realities of busy, complex lives — available virtually, across all 50 states, with providers who are genuinely committed to understanding your specific situation and building a care plan around it.
If anxiety or depression has been shaping your life in ways you’d like to change — whether that’s for months or for years — we’re here to help you take the first step. A conversation with one of our licensed providers is the beginning of finding out what’s actually possible for you.
Learn more about mental health care at Vantage
Frequently Asked Questions
What are the most effective treatments for anxiety and depression?
The strongest evidence supports cognitive behavioral therapy (CBT) and, for depression, interpersonal therapy — often combined with an SSRI or SNRI antidepressant when symptoms are moderate to severe. For treatment-resistant cases, options include ketamine or esketamine, TMS, and augmentation strategies. Best practice is individualized clinical evaluation.
Do I need medication or therapy?
It depends on symptom severity, personal preference, and past treatment history. Mild-to-moderate anxiety and depression often respond well to therapy alone; moderate-to-severe cases usually benefit from combined therapy and medication. A licensed provider can help you weigh the options.
How long does it take for treatment to work?
Therapy often shows measurable benefit within 4 to 8 weeks of weekly sessions, though many people notice improvements sooner. SSRIs typically take 4 to 6 weeks to reach full effect. Ketamine and esketamine can work within days for people with treatment-resistant depression.
What is CBT and how does it work?
Cognitive behavioral therapy (CBT) is a structured, evidence-based approach that helps you identify and change unhelpful thought patterns and behaviors. It is typically short-term — 12 to 20 sessions — and skills-focused. It has strong evidence for treating both anxiety and depression.
Are SSRIs safe long-term?
SSRIs have been studied for decades and are considered safe for long-term use for most people, with ongoing provider follow-up. Common side effects include gastrointestinal issues, sleep changes, and sexual side effects. As with any medication, benefits and risks should be discussed with a licensed provider.
What if my current treatment is not working?
The most important step is re-evaluation with your provider — sometimes adjustments in dose, medication class, therapy modality, or the addition of another treatment can make a significant difference. Treatment-resistant cases may benefit from newer options like ketamine or TMS. Do not give up — a fresh clinical review often opens new paths.
See how Vantage Telehealth can help — Get Started →
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Mental health conditions are serious medical concerns that require evaluation and care by licensed healthcare professionals. If you are experiencing a mental health crisis, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988. Always consult a qualified mental health provider before starting, stopping, or changing any mental health treatment. Vantage Telehealth’s mental health services are delivered by licensed providers who evaluate each patient individually.